cytarabine has been researched along with tanespimycin in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (75.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Bartl, F; Gdaniec, M; Przybylski, P; Pyta, K; Ruszkowski, P; Skrzypczak, N | 1 |
| Bali, P; Bhalla, K; Burnette, PK; Huang, M; Jove, R; Loughran, T; Nimmanapalli, R; O'Bryan, E; Tepperberg, J | 1 |
| Arlander, SJ; Dai, NT; Erlichman, C; Eyck, CJ; Flatten, K; Heldebrant, MP; Karnitz, LM; Karp, JE; Kaufmann, SH; Loegering, D; Mesa, RA; Powell, HL; Smith, BD; Vroman, BT | 1 |
| Allan, EK; Eaves, CJ; Elliott, MA; Godden, JL; Graham, SM; Holyoake, TL; Jørgensen, HG; Mountford, JC; Richmond, L | 1 |
| Armitage, ES; Balasis, M; Bali, P; Bhalla, K; Boyapalle, S; Fiskus, W; Greedy, B; Guo, F; Kumaraswamy, S; Lawrence, N; Pranpat, M; Rocha, K | 1 |
| Andreeff, M; Carew, JS; Huang, P; Keating, MJ; McQueen, TJ; Pelicano, H; Plunkett, W | 1 |
| Al Shaer, L; Burnett, A; Gilkes, A; Mills, K; Rowntree, C; Tonks, A; Walsby, E; Walsh, V | 1 |
| Adjei, AA; Ames, MM; Chen, Y; Erlichman, C; Flatten, KS; Greer, J; Hogan, W; Ivy, SP; Karnitz, LM; Karp, JE; Kaufmann, SH; Litzow, MR; Loegering, DA; Maurer, MJ; Mesa, RA; Peterson, KL; Reid, JM; Schneider, PA; Smith, BD; Steensma, DP | 1 |
1 trial(s) available for cytarabine and tanespimycin
| Article | Year |
|---|---|
Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Checkpoint Kinase 1; Cytarabine; Female; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Leukemia; Male; Middle Aged; Protein Kinases; Recurrence; Time Factors | 2011 |
7 other study(ies) available for cytarabine and tanespimycin
| Article | Year |
|---|---|
Synthesis, structure and anticancer activity of new geldanamycin amine analogs containing C(17)- or C(20)- flexible and rigid arms as well as closed or open ansa-bridges.
Topics: Amines; Antineoplastic Agents; Benzoquinones; Cell Proliferation; Cells, Cultured; Density Functional Theory; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Lactams, Macrocyclic; Molecular Structure; Structure-Activity Relationship | 2020 |
Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
Topics: Benzamides; Benzoquinones; Blast Crisis; Cytarabine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Enzyme Inhibitors; Fusion Proteins, bcr-abl; HL-60 Cells; Humans; Imatinib Mesylate; K562 Cells; Lactams, Macrocyclic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Milk Proteins; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Piperazines; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyridones; Pyrimidines; Rifabutin; src-Family Kinases; STAT5 Transcription Factor; Trans-Activators | 2002 |
Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine.
Topics: Antimetabolites, Antineoplastic; Benzoquinones; Checkpoint Kinase 1; Cytarabine; Drug Synergism; HL-60 Cells; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Leukemia, Myeloid, Acute; Protein Kinases; Rifabutin; RNA, Small Interfering; S Phase | 2005 |
Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzoquinones; Cell Line, Tumor; Cell Proliferation; Chromones; Cytarabine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Imatinib Mesylate; Lactams, Macrocyclic; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Morpholines; Piperazines; Piperidines; Pyridines; Pyrimidines; Rifabutin | 2005 |
Abrogation of heat shock protein 70 induction as a strategy to increase antileukemia activity of heat shock protein 90 inhibitor 17-allylamino-demethoxy geldanamycin.
Topics: Apoptosis; bcl-2-Associated X Protein; Benzhydryl Compounds; Benzoquinones; Combined Modality Therapy; Cytarabine; Drug Synergism; Etoposide; HL-60 Cells; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; K562 Cells; Lactams, Macrocyclic; Leukemia, Myeloid, Acute; Mitochondria; Protein Conformation; Pyrrolidinones; Rifabutin; RNA, Small Interfering | 2005 |
Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C.
Topics: Acute Disease; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzoquinones; Cytarabine; DNA; Drug Administration Schedule; Drug Antagonism; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; G1 Phase; HeLa Cells; HSP90 Heat-Shock Proteins; Humans; Jurkat Cells; Lactams, Macrocyclic; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid; Oxides; Sensitivity and Specificity; Structure-Activity Relationship; Tumor Cells, Cultured | 2006 |
Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Cell Death; Cytarabine; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Leukemia, Myeloid, Acute; MAP Kinase Signaling System; Middle Aged; Neoplasm Proteins; Signal Transduction; Tumor Cells, Cultured | 2008 |